PMID- 11025430
OWN - NLM
STAT- MEDLINE
DCOM- 20001227
LR  - 20171101
IS  - 0042-1138 (Print)
IS  - 0042-1138 (Linking)
VI  - 65
IP  - 2
DP  - 2000
TI  - Transurethral microwave thermotherapy for symptomatic benign prostatic 
      hyperplasia: short-term experience with Prostcare.
PG  - 89-94
AB  - PURPOSE: To assess our short-term experience with transurethral microwave 
      thermotherapy (TUMT) for symptomatic benign prostatic hyperplasia (BPH). PATIENTS 
      AND METHODS: From August 1993 through July 1994, in total 65 patients with 
      symptomatic BPH were enrolled into this study. The patients' ages ranged from 56 
      to 95 years with a mean of 70 years. Under local anesthesia with intraurethral 
      instillation of Xylocaine jelly only, all patients received one session of TUMT 
      for up to 60 min with Prostcare equipment. Uroflowmetry was performed and 
      international prostatic symptom score (IPSS) determined before 3 and 6 months 
      after TUMT for assessment of efficacy. All adverse events were recorded and 
      evaluated for clinical relevance. RESULTS: At 3 and 6 months following TUMT, the 
      mean IPSS decreased from 19.7 +/- 6.8 (baseline) to 12.8 +/- 8.2 (-46%) and to 
      15.5 +/- 9.0 (-21%), respectively; the maximal urine flow rate at 3 and 6 months 
      increased from 9.1 +/- 4.8 ml/s (baseline) to 11.0 +/- 4.9 ml/s (+21%) and to 
      10.9 +/- 5.6 ml/s (+19%), respectively. During TUMT, burning sensation was the 
      most frequent complaint (38.5%), followed by urethral discomfort (29.2%) and 
      urgency (9.2%). Two patients (3.1%) interrupted TUMT, because of intolerable 
      pain. Following TUMT micturition pain (73.8%) and gross hematuria (45.9%) were 
      the most adverse events. Most of these adverse events disappeared within 2 weeks. 
      One patient suffered from skin erosion over the penoscrotal junction 1 week 
      later. None had retrograde ejaculation; 1 patient complained of erectile 
      dysfunction. CONCLUSION: Although the efficacy of TUMT with Prostcare became less 
      prominent 6 months after TUMT, TUMT was still a tolerable, safe alternative 
      treatment of BPH, especially in patients who were not suitable for transurethral 
      resection of the prostate or anesthesia.
CI  - Copyright 2000 S. Karger AG, Basel
FAU - Tsai, Y S
AU  - Tsai YS
AD  - Department of Urology, National Cheng Kung University Hospital, Tainan, Taiwan.
FAU - Lin, J S
AU  - Lin JS
FAU - Tong, Y C
AU  - Tong YC
FAU - Tzai, T S
AU  - Tzai TS
FAU - Yang, W H
AU  - Yang WH
FAU - Chang, C C
AU  - Chang CC
FAU - Cheng, H L
AU  - Cheng HL
FAU - Lin, Y M
AU  - Lin YM
FAU - Jou, Y C
AU  - Jou YC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Urol Int
JT  - Urologia internationalis
JID - 0417373
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Diathermy/methods
MH  - Humans
MH  - Male
MH  - Microwaves/*therapeutic use
MH  - Middle Aged
MH  - Prostatic Hyperplasia/physiopathology/*therapy
MH  - Time Factors
MH  - Urethra
MH  - Urodynamics
EDAT- 2000/10/12 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/12 11:00
PHST- 2000/10/12 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/12 11:00 [entrez]
AID - 64846 [pii]
AID - 10.1159/000064846 [doi]
PST - ppublish
SO  - Urol Int. 2000;65(2):89-94. doi: 10.1159/000064846.